Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 2, 2005, Pages 191-201

  Shon, Ji Hong ^b   Yoon, Young Ran ^b   Hong, Won Seok ^b   Phuc, Minh Nguyen ^b   Lee, Sang Seop ^b   Choi, Young Gil ^b   Cha, In Jun ^b   Shin, Jae Gook ^a  

^a Inje University College of Medicine   (South Korea)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; FEXOFENADINE; GLYCOPROTEIN P INHIBITOR; HISTAMINE; ITRACONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; MALE; NORMAL HUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; URTICARIA;

ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; GENES, MDR; HAPLOTYPES; HISTAMINE H1 ANTAGONISTS; HUMANS; ITRACONAZOLE; MALE; POLYMORPHISM, GENETIC; TERFENADINE;

EID: 23444441477     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.04.012     Document Type: Article

References (41)

1. F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan, M.C. Willingham Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci U S A 84 1987 7735 7738
2. J.H. Lin, M. Yamazaki Role of P-glycoprotein in pharmacokinetics clinical implications Clin Pharmacokinet 42 2003 59 98
3. R.B. Kim Drugs as P-glycoprotein substrates, inhibitors, and inducers Drug Metab Rev 34 2002 47 54
4. J. Van Asperen, O. Van Tellingen, J.H. Beijnen The pharmacological role of P-glycoprotein in the intestinal epithelium Pharmacol Res 37 1998 429 435
5. M.M. Doherty, W.N. Charman The mucosa of the small intestine how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 41 2002 235 253
6. S. Hoffmeyer, O. Burk, O. von Richter, H.P. Arnold, J. Brockmoller, A. Johne Functional polymorphisms of the human multidrug-resistance gene multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 97 2000 3473 3478
7. R.B. Kim, B.F. Leake, E.F. Choo, G.K. Dresser, S.V. Kubba, U.I. Schwarz Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 2001 189 199
8. C. Marzolini, E. Paus, T. Buclin, R.B. Kim Polymorphisms in human MDR1 (P-glycoprotein) recent advances and clinical relevance Clin Pharmacol Ther 75 2004 13 33
9. E.L. Woodahl, R.J. Ho The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function Curr Drug Metab 5 2004 11 19
10. M. Drozdzik, M. Bialecka, K. Mysliwiec, K. Honczarenko, J. Stankiewicz, Z. Sych Polymorphism in the P-glycoprotein drug transporter MDR1 gene a possible link between environmental and genetic factors in Parkinson's disease Pharmacogenetics 13 2003 259 263
11. S. Gupta, J. Kim, S. Gollapudi Reversal of daunorubicin resistance in P388/ADR cells by itraconazole J Clin Invest 87 1991 1467 1469
12. E.J. Wang, K. Lew, C.N. Casciano, R.P. Clement, W.W. Johnson Interaction of common azole antifungals with P glycoprotein Antimicrob Agents Chemother 46 2002 160 165
13. J. Partanen, K.M. Jalava, P.J. Neuvonen Itraconazole increases serum digoxin concentration Pharmacol Toxicol 79 1996 274 276
14. K.M. Kaukonen, K.T. Olkkola, P.J. Neuvonen Itraconazole increases plasma concentrations of quinidine Clin Pharmacol Ther 62 1997 510 517
15. J.J. Lilja, J.T. Backman, J. Laitila, H. Luurila, P.J. Neuvonen Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol Clin Pharmacol Ther 73 2003 192 198
16. C. Lippert, J. Ling, P. Brown, S. Burmast, M. Eller, L. Cheng Mass balance and pharmacokinetics of MDL 16455A in healthy male volunteers [abstract] Pharmacol Res 12 1995 S390
17. M. Cvetkovic, B. Leake, M.F. Fromm, G.R. Wilkinson, R.B. Kim OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine Drug Metab Dispos 27 1999 866 871
18. M.A. Hamman, M.A. Bruce, B.D. Haehner-Daniels, S.D. Hall The effect of rifampin administration on the disposition of fexofenadine Clin Pharmacol Ther 69 2001 114 121
19. I. Hindmarch, Z. Shamsi, S. Kimber An evaluation of the effects of high-dose fexofenadine on the central nervous system a double-blind, placebo-controlled study in healthy volunteers Clin Exp Allergy 32 2002 133 139
20. M. Molimard, B. Diquet, M.S. Benedetti Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans Fundam Clin Pharmacol 18 2004 399 411
21. M. Tanabe, I. Ieiri, N. Nagata, K. Inoue, S. Ito, Y. Kanamori Expression of P-glycoprotein in human placenta relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene J Pharmacol Exp Ther 297 2001 1137 1143
22. J.V. Saarinen, R.J. Harvima, M. Horsmanheimo, I.T. Harvima Modulation of the immediate allergic wheal reaction in the skin by drugs inhibiting the effects of leukotriene C4 and prostaglandin D2 Eur J Clin Pharmacol 57 2001 1 4
23. L.M. Lucchesi, S. Pompeia, G.M. Manzano, A.F. Kohn, J.C.F. Galduroz, O.F.A. Bueno Flunitrazepam-induced changes in neurophysiological, behavioral, and subjective measures used to assess sedation Prog Neuropsychopharmacol Biol Psychiatry 27 2003 525 533
24. J. Zhi, J.W. Massarella, A.T. Melia, S.B. Teller, J. Schmitt-Muskus, T. Crews The pharmacokinetic-pharmacodynamic (Digit Symbol Substitution Test) relationship of flumazenil in a midazolam steady-state model in healthy volunteers Clin Pharmacol Ther 56 1994 530 536
25. J.E. Coutant, P.A. Westmark, P.A. Nardella, S.M. Walter, R.A. Okerholm Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection J Chromatogr 570 1991 139 148
26. V. Srivatsan, A.K. Dasgupta, P. Kale, R.R. Datla, D. Soni, M. Patel Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performance liquid chromatography J Chromatogr A 1031 2004 307 313
27. J.G. Shin, S.S. Lee Ethnic difference and polymorphisms of transporter proteins [abstract] Clin Exp Pharmacol Physiol 31 2004 A35
28. J.H. Shon, H.M. Chun, K.A. Kim, Y.R. Yoon, S.G. Shin, J.G. Shin The PK and PD of fexofenadine in relation to mdr1 genetic polymorphism in Korean healthy subjects [abstract] Clin Pharmacol Ther 71 2002 P71
29. S.Y. Yi, K.S. Hong, H.S. Lim, J.Y. Chung, D.S. Oh, J.R. Kim A variant 2677A allele of the MDR1 gene affects fexofenadine disposition Clin Pharmacol Ther 76 2004 418 427
30. C. Tannergren, T. Knutson, L. Knutson, H. Lennernas The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique Br J Clin Pharmacol 55 2003 182 190
31. C. Tannergren, N. Petri, L. Knutson, M. Hedeland, U. Bondesson, H. Lennernas Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine Clin Pharmacol Ther 74 2003 423 436
32. K. Venkatakrishnan, L.L. von Moltke, D.J. Greenblatt Effects of the antifungal agents on oxidative drug metabolism clinical relevance Clin Pharmacokinet 38 2000 111 180
33. M.F. Fromm The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans Adv Drug Deliv Rev 54 2002 1295 1310
34. J. Oh, C. Kimchi-Sarfaty, I. Kim, A. Sherman, S. Ambudkar, M. Gottesman Functional characterization of SNP and haplotype of human MDR1 gene using a vaccinia virus expression system [abstract] Clin Pharmacol Ther 77 2005 P24
35. T. Miyama, H. Takanaga, H. Matsuo, K. Yamano, K. Yamamoto, T. Iga P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier Antimicrob Agents Chemother 42 1998 1738 1744
36. N. Isoherranen, K.L. Kunze, K.E. Allen, W.L. Nelson, K.E. Thummel Role of itraconazole metabolites in CYP3A4 inhibition Drug Metab Dispos 32 2004 1121 1131
37. T. Russell, M. Stoltz, S. Weir Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers Clin Pharmacol Ther 64 1998 612 621
38. I. Ieiri, H. Takane, K. Otsubo The MDR1 (ABCB1) gene polymorphisms and its clinical implications Clin Pharmacokinet 43 2004 553 576
39. A.J. Sadeque, C. Wandel, H. He, S. Shah, A.J. Wood Increased drug delivery to the brain by P-glycoprotein inhibition Clin Pharmacol Ther 68 2000 231 237
40. F. Ridout, I. Hindmarch The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers Ann Allergy Asthma Immunol 90 2003 404 410
41. C. Chen, E. Hanson, J.W. Watson, J.S. Lee P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists Drug Metab Dispos 31 2003 312 318